{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:33:41Z","timestamp":1787668421941,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006739","name":"Capital Foundation of Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300155"],"award-info":[{"award-number":["82300155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62476274"],"award-info":[{"award-number":["62476274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270133"],"award-info":[{"award-number":["82270133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007422067"],"award-info":[{"award-number":["Z221100007422067"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["CX24PY25"],"award-info":[{"award-number":["CX24PY25"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012425","name":"Beijing Children's Hospital, Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2703100"],"award-info":[{"award-number":["2022YFC2703100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtha.2025.04.015","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:16:44Z","timestamp":1745500604000},"page":"2436-2448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-4590","authenticated-orcid":false,"given":"Zekun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanru","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaguang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-2420","authenticated-orcid":false,"given":"Man\u2212Chiu","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.04.015_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2025.04.015_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib3","first-page":"CD014544","article-title":"Nonclotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"2","author":"Olasupo","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2025.04.015_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib5","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse\u2212Jarres","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2025.04.015_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2012.01754.x","article-title":"Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice","volume":"88","author":"Benson","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2516.2008.01880.x","article-title":"The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy","volume":"15","author":"Dimichele","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele","year":"2002","journal-title":"Thromb Haemost"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2025.04.015_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: what have we learned over time?","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.12829","article-title":"Inhibitor eradication with rituximab in haemophilia: where do we stand?","volume":"165","author":"Franchini","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1538-7836.2009.03332.x","article-title":"Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib14","first-page":"e469","article-title":"A low-dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high-titre factor VIII inhibitor and poor-ITI prognostic risk","volume":"27","author":"Li","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12562","article-title":"Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors","volume":"5","author":"Li","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2004.04916.x","article-title":"Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia","volume":"125","author":"Mathias","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/s-0037-1612589","article-title":"Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs","volume":"95","author":"Mateo","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2006.01215.x","article-title":"Rituximab for adolescents with haemophilia and high titre inhibitors","volume":"12","author":"Fox","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2516.2006.01185.x","article-title":"Rituximab in the treatment of high responding inhibitors in severe haemophilia A","volume":"12","author":"Moschovi","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1365-2516.2008.01839.x","article-title":"Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients\u2019 analysis","volume":"14","author":"Franchini","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0037-1617028","article-title":"Inhibitor treatment by rituximab in congenital haemophilia A\u2014two case reports","volume":"29","author":"Streif","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.04.015_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-0038-1657777","article-title":"ABIRISK consortium. Inhibitor formation in congenital hemophilia A: an immunological perspective","volume":"44","author":"Delignat","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.12065","article-title":"Dangerous liaisons: how the immune system deals with factor VIII","volume":"11","author":"Wroblewska","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"Suppl 4","key":"10.1016\/j.jtha.2025.04.015_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2516.2012.02827.x","article-title":"Prevention and prediction of inhibitor risk","volume":"18","author":"Astermark","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1172\/JCI73316","article-title":"Emerging roles of lymphatic endothelium in regulating adaptive immunity","volume":"124","author":"Card","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.04.015_bib27","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2017-05-782912","article-title":"Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A","volume":"130","author":"Zerra","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.04.015_bib28","article-title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs","volume":"132","author":"Becker\u2212Gotot","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.04.015_bib29","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating Factor VIII: Recent Progress","volume":"10","author":"Lacroix\u2212Desmazes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.jtha.2025.04.015_bib31","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/jth.13961","article-title":"Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement","volume":"16","author":"Spena","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2016.10.015","article-title":"Current view and outcome of ITI therapy\u2014a change over time?","volume":"148","author":"Holstein","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.04.015_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/hae.14431","article-title":"Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors","volume":"28","author":"Di","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib34","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1055\/s-0042-1748756","article-title":"Immune tolerance induction (ITI) with a pdFVIII\/VWF concentrate (octanate) in 100 patients in the Observational ITI (ObsITI) study","volume":"6","author":"Escuriola Ettingshausen","year":"2022","journal-title":"TH Open"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2025.04.015_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.12466","article-title":"ITI choice for the optimal management of inhibitor patients\u2014from a clinical and pharmacoeconomic perspective","volume":"20","author":"Oldenburg","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib36","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.04.015_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0038-1648828","article-title":"Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee","volume":"72","author":"Mariani","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.04.015_bib39","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"Coppola","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fimmu.2020.01293","article-title":"B cell depletion eliminates FVIII memory B cells and enhances aav8-cof8 immune tolerance induction when combined with rapamycin","volume":"11","author":"Biswas","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib41","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3389\/fimmu.2018.02673","article-title":"Long-lived plasma cells in mice and men","volume":"9","author":"Brynjolfsson","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.04.015_bib43","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/bloodadvances.2022007267","article-title":"Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication","volume":"7","author":"Paul","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.04.015_bib44","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1172\/JCI118558","article-title":"Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A","volume":"97","author":"Gilles","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.04.015_bib45","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/hae.14381","article-title":"Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update","volume":"27","author":"Hart","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.04.015_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"Ljung","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.15053","article-title":"How I manage patients with inherited haemophilia A and B and factor inhibitors","volume":"180","author":"Ljung","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142906","article-title":"B cell-activating factor modulates the factor VIII immune response in hemophilia A","volume":"131","author":"Doshi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.04.015_bib49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3389\/fimmu.2020.01219","article-title":"Hemophilia A inhibitor subjects show unique PBMC gene expression profiles that include up-regulated innate immune modulators","volume":"11","author":"Karim","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0040-1722353","article-title":"Effect of the first factor VIII infusions on immunological biomarkers in previously untreated patients with hemophilia A from the HEMFIL study","volume":"121","author":"de Oliveira","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.04.015_bib51","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1172\/JCI81859","article-title":"IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII","volume":"125","author":"Matino","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.04.015_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16377","article-title":"Advances in knowledge of inhibitor formation in severe haemophilia A","volume":"189","author":"Cormier","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.04.015_bib53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3324\/haematol.2017.165720","article-title":"Complement C3 is a novel modulator of the anti-factor VIII immune response","volume":"103","author":"Rayes","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.04.015_bib54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fimmu.2020.00905","article-title":"Fc gamma receptors and complement component 3 facilitate anti-FVIII antibody formation","volume":"11","author":"Zerra","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtha.2025.04.015_bib56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2011.04.007","article-title":"Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1\/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells","volume":"140","author":"Chen","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4049\/jimmunol.1201827","article-title":"YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-kappaB pathways, causing bronchial smooth muscle proliferation and migration","volume":"190","author":"Tang","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jtha.2025.04.015_bib58","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3390\/cells9071716","article-title":"CD38: T cell immuno-metabolic modulator","volume":"9","author":"Kar","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2025.04.015_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: an important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtha.2025.04.015_bib60","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.27215","article-title":"Calcium-mediated shaping of naive CD4 T-cell phenotype and function","volume":"6","author":"Guichard","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.jtha.2025.04.015_bib61","first-page":"143","article-title":"Acquired hemophilia A: emerging treatment options","volume":"6","author":"Janbain","year":"2015","journal-title":"J Blood Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:47:32Z","timestamp":1785552452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362500265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S153878362500265X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.04.015","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}